Emergent BioSolutions Inc.
General ticker "EBS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $503.3M (TTM average)
Emergent BioSolutions Inc. does not follow the US Stock Market performance with the rate: -25.2%.
Estimated limits based on current volatility of 3.4%: low 6.59$, high 7.04$
Factors to consider:
- Total employees count: 900 (0.0%) as of 2025
- US accounted for 71.5% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Market demand decline, USG contract loss, Manufacturing disruptions, Clinical trial failure, Market competition
- Current price 27.4% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.78$, 16.21$]
- 2026-12-31 to 2027-12-31 estimated range: [7.49$, 14.28$]
Financial Metrics affecting the EBS estimates:
- Positive: with PPE of 8.3 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 25.61 > 24.19
- Positive: 11.29 < Operating profit margin, % of 13.47
- Positive: Investing cash flow per share per price, % of 10.42 > 2.08
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -1.98
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Positive: 3.48 < Return on assets ratio (scaled to [-100,100]) of 3.84
- Positive: Interest expense per share per price, % of 8.90 <= 10.35
- Positive: 34.41 < Shareholder equity ratio, % of 39.63 <= 42.26
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term EBS quotes
Long-term EBS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,049.30MM | $1,043.60MM | $742.90MM |
| Operating Expenses | $1,775.70MM | $1,152.30MM | $642.80MM |
| Operating Income | $-726.40MM | $-108.70MM | $100.10MM |
| Non-Operating Income | $-4.80MM | $-34.20MM | $-17.30MM |
| Interest Expense | $87.90MM | $71.00MM | $59.30MM |
| R&D Expense | $111.40MM | $70.70MM | $53.20MM |
| Income(Loss) | $-731.20MM | $-142.90MM | $82.80MM |
| Taxes | $29.30MM | $47.70MM | $30.20MM |
| Net Income(Loss)* | $-760.50MM | $-190.60MM | $52.60MM |
| Stockholders Equity | $649.30MM | $482.80MM | $522.60MM |
| Assets | $1,823.20MM | $1,389.70MM | $1,318.60MM |
| Operating Cash Flow | $-206.30MM | $58.70MM | $170.60MM |
| Capital expenditure | $51.60MM | $22.90MM | $13.80MM |
| Investing Cash Flow | $212.30MM | $125.20MM | $69.40MM |
| Financing Cash Flow | $-535.70MM | $-190.00MM | $-136.60MM |
| Earnings Per Share** | $-14.85 | $-3.60 | $0.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.